Beni Surpin is a partner and transactional lawyer with Foley & Lardner LLP, where his focus is on global technology and commercial transactions. Mr. Surpin counsels international and domestic companies on legal and business issues relating to technology, intellectual property and commercial deals across a wide range of industries, including in the wireless, high-tech, health care, medical devices, life sciences, automotive, aviation, food and beverage, and fashion and apparel sectors. His practice focuses on collaborations involving technology transfer between companies to enhance product lines and services through access to new technologies. He works closely with his clients in creating and setting strategic direction and then structuring relationships and negotiating deals to implement these goals.
Mr. Surpin’s experience covers a broad spectrum of deals and structures through technology licenses and acquisitions, service-based platforms, manufacturing, supply and distribution arrangements, clinical, research and development agreements, royalty monetizations, joint ventures, and strategic partnerships and alliances. He also works with private and public companies to maximize value and revenue from intellectual property and technology portfolios and in settling IP disputes and litigation in a way that allows them to optimize their assets, advising them on a variety of related legal and business issues.
With additional experience in the areas of corporate governance and business, private equity, leveraged debt financing, and real estate investments and funds, Mr. Surpin also guides emerging growth entities, middle market companies, and multinational corporations in their strategic planning, development and growth.
Prior to joining Foley, Mr. Surpin was a partner with an international law firm where he headed the global technology, intellectual property and commercial transactions group, and the China intellectual property team. He has also resided in the UK, Brazil and Israel.
Expanding the Possibilities of Personalized Medicine Through Collaborative Data Collection, Sharing, and Analysis
2:05 PM - 2:55 PM